GLP Watchdog

Gimme Care vs Hims

Hims has an open FDA warning letter dated September 9, 2025. Gimme Care has none. No price lines up like for like: Gimme Care and Hims publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Gimme Care / Hims

Gimme Care logo

Gimme Care

8.5/10

Hims logo

Hims

6.7/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$160/moCompounded semaglutide injection
$149/moBrand-name semaglutide pill, medication only, membership extra
States
All 50 states and DC
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Gimme Care
Visit Hims

Neither Gimme Care nor Hims pays us. Links to them earn nothing. Scores: Gimme Care 8.5, Hims 6.7. How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. Gimme Care has none.

  2. 02

    Gimme Care names no compounding pharmacy in our record. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like: Gimme Care and Hims publish prices for different products.

  4. 04

    Only Gimme Care lists a price for compounded semaglutide injection and compounded tirzepatide injection. Only Hims lists a price for brand-name semaglutide pen, brand-name tirzepatide pen and brand-name semaglutide pill.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Gimme Care

Hims

Compounded semaglutide injection

$160/mo

$1,920 a year

Not sold or not priced
Compounded tirzepatide injection

$199/mo

$2,388 a year

Not sold or not priced
Brand-name semaglutide pen
Not sold or not priced

$199/mo

medication only, membership extra; not compared

Brand-name tirzepatide pen
Not sold or not priced

$299/mo

medication only, membership extra; not compared

Brand-name semaglutide pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Foundayo (orforglipron) pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Price includes
Medication, clinician visits, shipping
Medication
Billed separately
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly cycle
Monthly membership, auto-renews
Refunds
Full refund if canceled before the pharmacy ships; dispensed medication is final sale
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Early-exit fee
None stated
None stated

Read off each seller’s own pages. Gimme Care: October 17, 2026. Hims: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Gimme Care

8.5/10
  • No FDA warning letter on record
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Hims does not price
  • Price includes clinician visits
  • Names no compounding pharmacy
Visit Gimme Care

The case for Hims

6.7/10
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Gimme Care does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

Scores

Gimme Care 8.5 · Hims 6.7 out of 10. Six weighted parts.

Value25%

7.2A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

8.5A
vs
B
6.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
3.0

The score is the same formula for every seller. Payment does not enter it. Method

Gimme Care vs Hims: questions

Hims has an open FDA warning letter dated September 9, 2025. Gimme Care has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Gimme Care names no compounding pharmacy in our record. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like: Gimme Care and Hims publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Gimme Care states you can cancel at any time; refunds: full refund if canceled before the pharmacy ships; dispensed medication is final sale. Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed.
Neither Gimme Care nor Hims pays us. Links to them earn nothing. Scores: Gimme Care 8.5, Hims 6.7.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks